Css LLC Aldeyra Therapeutics, Inc. Call Options Transaction History

Css LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Nov 14, 2022	SELL	$3.8 - $7.74 $178,220 - $363,006	-46,900 Reduced 41.5%	66,100 $353,000
Q2 2022 Aug 15, 2022	BUY	$2.43 - $4.85 $201,690 - $402,549	83,000 Added 276.67%	113,000 $451,000
Q1 2022 May 16, 2022	BUY	$3.25 - $5.17 $14,625 - $23,265	4,500 Added 17.65%	30,000 $133,000
Q4 2021 Feb 14, 2022	BUY	$3.5 - $9.63 $89,250 - $245,565	25,500 New	25,500 $102,000
Q3 2021 Nov 15, 2021	SELL	$7.94 - $11.31 $721,746 - $1.03 Million	-90,900 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$10.44 - $14.85 $930,204 - $1.32 Million	89,100 Added 4950.0%	90,900 $1.03 Million
Q1 2021 May 17, 2021	BUY	$6.53 - $14.42 $11,754 - $25,956	1,800 New	1,800 $21,000

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $280M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Css LLC, based on Form 13F filings with the SEC.

Stay updated on Css LLC with notifications on news.